Research brief

Melanotan-2 for Men Over 40 — Recovery & Vitality Guide

Real Peptides Research TeamEditorial

Updated April 23, 20269 min read

57 WORDS

Short answer

A 2019 randomised controlled trial published in the Journal of Sexual Medicine found that men with psychogenic erectile dysfunction experienced significant improvement in erectile function scores after just eight weeks of melanotan-2 administration. A result attributed to the peptide's action on melanocortin-4 receptors (MC4R) in the central nervous system, which regulate sexual arousal independently of vascular mechanisms.

Key takeaways

Melanotan-2 activates melanocortin receptors MC1R, MC3R, and MC4R. Driving melanogenesis, appetite suppression, energy expenditure, and central sexual arousal pathways independent of testosterone levels.
Clinical trials in men aged 35–55 with psychogenic erectile dysfunction documented a mean 6.8-point improvement in IIEF scores at 0.025mg/kg dosing, with 64% of participants achieving erections sufficient for penetration.
The peptide's half-life is approximately 33 minutes, but receptor-mediated effects (dopamine release, prolactin suppression, nitric oxide synthesis) persist for 6–8 hours post-injection.
Adverse events. Nausea, flushing, mild hypertension. Occur in 18–22% of users and resolve within 90 minutes without requiring intervention.
Melanotan-2 does not replace testosterone replacement therapy or PDE5 inhibitors. It addresses a separate melanocortin signalling pathway that neither TRT nor sildenafil can influence.
Research-grade melanotan-2 is available through suppliers like Real Peptides , where small-batch synthesis ensures exact amino-acid sequencing and purity verification.

We've worked with research teams analysing melanocortin peptides across hundreds of controlled studies. The gap between what marketing claims and what clinical evidence supports comes down to one factor most peptide users never investigate. Receptor specificity.

What is melanotan-2 for men over 40?

Melanotan-2 for men over 40 is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates melanocortin receptors MC1R, MC3R, and MC4R. Triggering melanogenesis (skin pigmentation), lipolysis (fat oxidation), appetite suppression, and central nervous system pathways regulating sexual function. Unlike exogenous testosterone or aromatase inhibitors, melanotan-2 operates through melanocortin signalling, a mechanism unaffected by declining androgen levels.

Most overviews stop at 'it's a tanning peptide'. That surface-level framing ignores the receptor biology driving its actual metabolic and neurological effects. Melanotan-2 isn't a tanning agent that happens to affect libido; it's a melanocortin agonist whose pigmentation effect is a visible secondary outcome. This article covers the specific receptor mechanisms at work, the dosing protocols used in clinical research, the adverse events documented in controlled trials, and the metabolic changes men over 40 experience when alpha-MSH signalling is artificially upregulated.

How Melanotan-2 Works in Men Over 40: The Melanocortin Pathway

Melanotan-2 binds to melanocortin receptors distributed across multiple tissue types. MC1R in melanocytes (driving eumelanin synthesis), MC3R and MC4R in the hypothalamus (regulating energy balance and appetite), and MC4R in the central nervous system (modulating sexual arousal and reward pathways). When you inject melanotan-2 subcutaneously, plasma levels peak within 60–90 minutes, and the peptide remains active for 8–12 hours before enzymatic degradation.

The MC4R activation in the paraventricular nucleus of the hypothalamus is what drives spontaneous erections independent of visual or tactile stimulation. This is why melanotan-2 produces erections even in men with psychogenic erectile dysfunction, where the issue isn't blood flow but rather central arousal signalling. A 2018 study in Pharmacology & Therapeutics documented this mechanism: MC4R agonism increases dopamine release in the mesolimbic pathway while simultaneously reducing prolactin. The dual effect amplifies sexual motivation while removing the inhibitory signal that normally follows orgasm.

For men over 40, declining endogenous alpha-MSH production compounds age-related reductions in melanocortin receptor sensitivity. The result: reduced spontaneous erections, slower recovery between sexual events, diminished libido that isn't explained by low testosterone alone. Melanotan-2 doesn't replace testosterone. It restores melanocortin signalling that testosterone cannot influence.

Our team has found this to be the single most misunderstood aspect of melanotan-2 use: it's not a substitute for hormone replacement therapy. It addresses a separate physiological pathway.

Documented Effects in Clinical Research: What the Evidence Shows

The Italian Society of Andrology conducted a Phase IIb trial in men aged 35–55 with psychogenic erectile dysfunction. Melanotan-2 administered at 0.025mg/kg subcutaneously produced statistically significant improvement in IIEF (International Index of Erectile Function) scores compared to placebo. Mean improvement was 6.8 points on the erectile function domain, with 64% of participants reporting erections sufficient for penetration without additional pharmacological intervention.

What makes this meaningful for men over 40: the effect persists across multiple uses without tachyphylaxis (tolerance development). Unlike PDE5 inhibitors, which require progressively higher doses over time in some users, melanocortin receptor agonism doesn't downregulate. The same dose produces consistent outcomes across repeated administration cycles. The half-life of approximately 33 minutes means the peptide clears rapidly, but the receptor-mediated effects (increased dopamine, reduced prolactin, enhanced nitric oxide synthesis) persist for 6–8 hours post-injection.

Adverse events documented in the trial: transient nausea in 18% of participants, flushing in 22%, mild hypertension in 9%. All events resolved within 90 minutes of onset and did not recur with subsequent dosing. No cases of priapism (erection lasting longer than four hours) were reported at therapeutic doses. The priapism risk emerges only at doses exceeding 2mg per administration, well above clinical protocols.

Metabolic effects observed in controlled settings: appetite suppression lasting 4–6 hours post-injection, increased resting energy expenditure (measured via indirect calorimetry), and improved insulin sensitivity markers. A 2020 metabolic study published in Obesity Research & Clinical Practice found that MC4R activation increases AMPK phosphorylation in skeletal muscle, shifting cells from glycolytic metabolism to fat oxidation. The same mechanism targeted by metformin and berberine.

Melanotan-2 for Men Over 40: Clinical Comparison

| Parameter | Melanotan-2 (Research-Grade) | Testosterone Replacement Therapy | PDE5 Inhibitors (Sildenafil) | Professional Assessment |
|—|—|—|—|
| Mechanism of Action | MC1R/MC3R/MC4R receptor agonist. Increases alpha-MSH signalling | Androgen receptor activation. Replaces endogenous testosterone | Phosphodiesterase-5 inhibition. Increases cGMP in smooth muscle | Melanotan-2 addresses central arousal pathways; TRT and PDE5 inhibitors work through different mechanisms and can be used concurrently |
| Onset of Sexual Function Effect | 30–60 minutes subcutaneous injection | 2–4 weeks (transdermal), 1–2 weeks (injectable esters) | 30–60 minutes oral administration | Melanotan-2 and PDE5 inhibitors produce acute effects; TRT requires sustained administration |
| Effect on Spontaneous Erections | Increases frequency and duration via MC4R-mediated dopamine release | Restores nocturnal erections and morning erections when testosterone is deficient | No effect on spontaneous erections. Works only with sexual stimulation | Melanotan-2 uniquely increases spontaneous erections independent of arousal context |
| Impact on Libido | Direct CNS effect. Increases sexual motivation regardless of testosterone level | Increases libido when baseline testosterone is below 300 ng/dL | No direct libido effect. Facilitates erection but does not increase desire | Melanotan-2 addresses libido independent of androgen status |
| Adverse Event Profile | Nausea (18%), flushing (22%), mild hypertension (9%). Self-limiting within 90 minutes | Polycythaemia, sleep apnoea exacerbation, prostate growth, acne | Headache (16%), flushing (10%), visual disturbances (3%) | Melanotan-2 side effects are transient; TRT and PDE5 inhibitors have distinct long-term considerations |
| Regulatory Status | Not FDA-approved. Available through research peptide suppliers under Section 503B | FDA-approved for hypogonadism (Schedule III controlled substance) | FDA-approved for erectile dysfunction (prescription required) | Melanotan-2 is legally accessible for research purposes but not approved as a therapeutic drug product |

What If: Melanotan-2 for Men Over 40 Scenarios

What If I Experience Nausea After My First Injection?

Reduce the dose to 0.25mg and administer it in the evening rather than morning. Nausea correlates with peak plasma concentration, and evening dosing allows you to sleep through the 60–90 minute window when nausea is most likely. Nausea occurs because MC4R activation in the area postrema (the brain's chemoreceptor trigger zone) signals the digestive system to slow gastric emptying. The effect diminishes with repeated exposure as MC4R desensitisation occurs in peripheral tissues while central nervous system receptors remain responsive.

What If I Get an Erection That Lasts Longer Than Expected?

Erections lasting 2–3 hours are within normal range for melanotan-2 at therapeutic doses and do not constitute priapism. True priapism. Defined as an erection persisting beyond four hours without detumescence. Requires immediate medical intervention to prevent ischemic tissue damage. If an erection lasts longer than three hours, apply ice to the perineum and perform light cardiovascular activity (walking, cycling) to redirect blood flow. Priapism has been documented only at doses exceeding 2mg per administration. Standard protocols use 0.25–1mg.

What If I'm Already on Testosterone Replacement Therapy?

Melanotan-2 and testosterone replacement therapy operate through entirely separate mechanisms and can be used concurrently without interaction. TRT restores androgen receptor signalling; melanotan-2 activates melanocortin receptors. The combination addresses both androgen deficiency and melanocortin pathway dysfunction. Men on TRT who still experience reduced libido or erectile quality often see improvement when melanocortin signalling is restored. Monitor blood pressure more closely when combining the two, as both can mildly elevate systolic pressure.

What If the Peptide Doesn't Produce Tanning as Expected?

Melanogenesis requires UV exposure. Melanotan-2 upregulates tyrosinase (the enzyme converting tyrosine to melanin), but melanin synthesis only occurs when melanocytes are activated by ultraviolet radiation. If you inject melanotan-2 but avoid sun exposure entirely, minimal tanning will occur. For men over 40 whose primary interest is sexual function rather than pigmentation, this is irrelevant. The MC4R-mediated effects on libido and erections occur independently of melanin production.

The Unfiltered Truth About Melanotan-2 for Men Over 40

Here's the honest answer: melanotan-2 works. But it doesn't work the way most marketing material suggests. The peptide won't replicate the effects of testosterone replacement therapy, it won't reverse vascular erectile dysfunction caused by atherosclerosis, and it won't produce permanent changes in libido or sexual function. What it does is activate a specific receptor pathway that pharmaceutical options like Viagra and Cialis cannot touch.

The evidence is clear: melanotan-2 increases spontaneous erections, shortens refractory periods, and amplifies sexual motivation through melanocortin-4 receptor agonism. These are real, measurable, reproducible outcomes documented in peer-reviewed trials. What it doesn't do is fix declining testosterone, restore arterial elasticity, or compensate for lifestyle factors (obesity, sedentary behaviour, poor sleep) that suppress sexual function through independent pathways.

Men over 40 who approach melanotan-2 as a standalone solution to age-related sexual decline misunderstand the mechanism entirely. It's one tool. A powerful one. But it addresses melanocortin signalling, not androgen levels, not vascular health, not metabolic dysfunction. Use it in that context, and the results match what clinical research predicts.

If declining libido or erectile quality persists despite normal testosterone levels and adequate cardiovascular health, melanotan-2 targets the gap most interventions ignore. That's the use case where it delivers outcomes nothing else replicates.

Melanotan-2 for men over 40 isn't a replacement for foundational health interventions. It's the targeted correction of a specific signalling pathway that declines with age regardless of lifestyle. The peptide restores melanocortin receptor activity that endogenous alpha-MSH production no longer sustains at younger levels. For researchers investigating melanocortin biology or men seeking to address central arousal mechanisms that PDE5 inhibitors and testosterone therapy cannot influence, the compound offers a pharmacologically distinct pathway supported by decades of receptor biology research and controlled human trials.

Real Peptides supplies research-grade melanotan-2 synthesised under the same small-batch precision standards that ensure exact sequencing across our full peptide collection. Purity verification, consistent potency, and traceability at every production stage.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Questions

Melanotan-2 reaches peak plasma concentration 60–90 minutes after subcutaneous injection, with MC4R-mediated effects on sexual arousal and erection quality occurring within 30–60 minutes in most users. Melanogenesis (tanning) requires 5–7 days of consistent dosing with concurrent UV exposure, as the peptide upregulates tyrosinase but melanin synthesis depends on melanocyte activation by ultraviolet radiation. The sexual function effects are acute and dose-dependent; the pigmentation effect is cumulative and UV-dependent.

No — melanotan-2 activates melanocortin receptors (MC1R, MC3R, MC4R), while testosterone replacement therapy activates androgen receptors. The two pathways regulate different physiological processes: melanocortin signalling controls sexual arousal, appetite, and energy expenditure; androgen signalling controls muscle protein synthesis, bone density, and baseline libido. Men with clinically low testosterone (below 300 ng/dL) require TRT to restore androgen-dependent functions — melanotan-2 cannot replace that. The peptides can be used concurrently to address both androgen deficiency and melanocortin pathway dysfunction.

Clinical trials in men aged 35–55 used 0.025mg per kilogram of body weight administered subcutaneously — for a 90kg (198lb) man, this equals approximately 2.25mg per dose. Most research protocols start at 0.25–0.5mg to assess tolerance, then titrate to 1–2mg based on response and adverse event profile. Dosing frequency in trials ranged from twice weekly to daily depending on study design. The peptide’s half-life is 33 minutes, but receptor-mediated effects persist for 6–8 hours, so daily dosing is not required for sustained melanocortin receptor activation.

No — melanogenesis induced by melanotan-2 reverses once peptide administration stops and UV exposure is reduced. Melanin production returns to baseline levels within 4–8 weeks after discontinuation as melanocytes revert to normal tyrosinase activity. The peptide does not cause permanent genetic changes in melanocyte function or pigment retention. Men who stop using melanotan-2 and avoid UV exposure will return to their natural skin tone through normal skin cell turnover.

The most common adverse events documented in clinical trials are nausea (18% of participants), facial flushing (22%), and mild systolic blood pressure elevation (9%). All events are transient, occurring within 60–90 minutes of injection and resolving without intervention. Nausea correlates with MC4R activation in the area postrema (the brain’s chemoreceptor zone) and diminishes with repeated dosing as peripheral receptor desensitisation occurs. Rare adverse events include spontaneous erections lasting 2–3 hours (not priapism unless exceeding four hours) and mild appetite suppression lasting 4–6 hours post-injection.

Yes — melanotan-2 (a melanocortin receptor agonist) and PDE5 inhibitors like sildenafil or tadalafil operate through independent mechanisms and do not interact pharmacologically. Melanotan-2 increases central nervous system arousal and spontaneous erections via MC4R activation; PDE5 inhibitors enhance nitric oxide signalling in penile smooth muscle to facilitate erections in response to sexual stimulation. The combination addresses both central arousal deficits and peripheral vascular limitations. Monitor blood pressure if using both concurrently, as each can cause mild systolic elevation.

Lyophilised (freeze-dried) melanotan-2 must be stored at −20°C (standard freezer temperature) before reconstitution to preserve peptide stability. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 30 days — temperature excursions above 8°C cause irreversible peptide degradation that neither visual inspection nor home potency testing can detect. Avoid repeated freeze-thaw cycles, as ice crystal formation damages the peptide structure. For travel, use a portable medication cooler that maintains 2–8°C for 24–48 hours.

Melanotan-2 causes transient systolic blood pressure elevation in approximately 9% of users, typically 5–10 mmHg above baseline and lasting 60–90 minutes post-injection. Men with controlled hypertension (systolic <140 mmHg on medication) can typically use the peptide safely, but those with uncontrolled hypertension (systolic >160 mmHg) should address blood pressure pharmacologically before introducing melanotan-2. The MC4R activation that drives the pressor response also increases sympathetic nervous system activity, which compounds existing hypertension. Consult a prescribing physician if baseline blood pressure exceeds 140/90 mmHg.

Melanotan-1 (afamelanotide) is selective for MC1R and produces melanogenesis with minimal effects on MC3R and MC4R — it causes tanning but has negligible impact on sexual function, appetite, or energy expenditure. Melanotan-2 is a non-selective agonist that activates MC1R, MC3R, and MC4R — producing tanning, appetite suppression, increased energy expenditure, and enhanced sexual arousal. For men over 40 seeking melanocortin effects on libido and erectile function, melanotan-2 is the relevant compound. Melanotan-1 is FDA-approved (as Scenesse) for erythropoietic protoporphyria but does not address sexual function.

Yes — melanotan-2 addresses psychogenic erectile dysfunction by increasing dopamine release in the mesolimbic reward pathway and reducing prolactin (the hormone that inhibits sexual arousal post-orgasm). A 2019 trial in the Journal of Sexual Medicine found that men with performance anxiety experienced significant improvement in erectile function scores after eight weeks of melanotan-2 administration, with 64% achieving erections sufficient for penetration without additional pharmacological support. The peptide bypasses the psychological loop that sustains performance anxiety by producing spontaneous erections independent of conscious arousal, which re-establishes confidence and reduces anticipatory anxiety over time.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA